DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design

Objective

• SVR₁₂ (HCV RNA < 15 IU/ml), with 95% CI, by ITT
• Superiority if lower limit of the 95% CI > SVR₁₂ rate of 61% of a historical control (SMV + PEG-IFN + RBV) from a composite endpoint in RESTORE study

Baseline characteristics

Adverse events, %

Summary

• SMV + SOF for 12 weeks resulted in overall 100% SVR₁₂ in genotype 4 HCV infected patients
  • With or without cirrhosis
  • Whether naïve or IFN-PEG + RBV pretreated
• Treatment was safe and well tolerated, all adverse events being of grade 1 or 2